Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 353.60
Bid: 354.80
Ask: 355.40
Change: 0.00 (0.00%)
Spread: 0.60 (0.169%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 353.60
QQ. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Fourth Quarter Trading Update

20 Apr 2022 07:00

RNS Number : 6600I
QinetiQ Group plc
20 April 2022
 

News release

 

QinetiQ Group plc

Fourth Quarter Trading Update

20 April 2022 - QinetiQ Group plc ("QinetiQ" or "the Group") today issues a trading update covering its fourth quarter to 31 March 2022.

Strong operational performance in fourth quarter - ahead of full year guidance

Through continued disciplined execution of our strategy, the Group has delivered strong operational performance through the fourth quarter. Today we are pleased to announce that we expect our results for the full year to 31 March 2022 to be marginally ahead of our previous guidance and current market consensus expectations.

Full year order intake has been very strong at more than £1.2bn and, subject to audit, we expect to deliver c.5% revenue growth on an organic basis with underlying operating profit of at least £135m. Operating cash flow has been excellent and we retain a strong balance sheet with net cash at 31 March 2022 of c.£225m.

Our strong performance has been driven by significant growth in EMEA Services, partially offset by the slower recovery in Global Products. We saw continued excellent growth in Australia and the UK driven by good programme execution and delivery across all our major contracts. US revenue performance recovery was slower than expected, with the second half in line with the first half, largely due to the US defence budget being constrained by the extended Continuing Resolution. However, we secured 20% year-on-year growth in order intake which, coupled with our new leadership team, provides a strong foundation for the delivery of our US growth strategy. The complex project contract is now closed and the financial impact remains the £14.5m write-down fully contained in our first half results.

We retain our medium to long-term guidance: we are targeting mid-single digit percentage compound annual organic revenue growth over the next five years, with strategic acquisitions further enhancing this growth. We are targeting a long-term operating profit margin of 12-13%, although in the short-term we anticipate margins being c.100bps lower, driven by inflationary pressures and continued investment. Capital expenditure for FY23 is expected to be at the upper end of the £90m to £120m per annum range, consistent with our previous guidance.

Steve Wadey, Group Chief Executive Officer said:

"I am extremely proud of how our people have continued to deliver critical defence and security capabilities for our customers, despite the ongoing challenges of the pandemic. Recent world events have reinforced the long-term needs of our customers, including capabilities utilising differentiated technology, test and training solutions which are directly aligned with our strategy. With a clear focus on disciplined execution of our strategy, increasing demand for our solutions and good revenue coverage, we have positive momentum to deliver sustainable growth in the coming years and are maintaining expectations for Group performance."

Investor seminar 27 April 2022

We are hosting an investor seminar on 27 April 2022 at The Smith Centre at The Science Museum, Exhibition Road, South Kensington, London, SW7 2DD. The presentation will cover our global ambition with a particular focus on the US and Australia. You are invited to join us for lunch from 12.30pm BST to see a selection of our products and capabilities, as well as meeting the QinetiQ Leadership Team. The presentation will run 1.30-3.30pm BST and there will be an option to view online if you cannot join us in person. More information including how to register can be found on our website here:

https://www.qinetiq.com/en/investors/investor-seminars/delivering-global-growth

Preliminary results

We will announce our preliminary results on 19 May 2022. We will be hosting an in-person results presentation, details of which will be available on our website shortly at: www.QinetiQ.com/investors.

About QinetiQ

QinetiQ (QQ.L) is a leading science and engineering company operating primarily in the defence and security markets. We work in partnership with our customers to solve real world problems through innovative solutions delivering operational and competitive advantage. Visit our website www.QinetiQ.com. Follow us on LinkedIn and Twitter @QinetiQ. Visit our blog www.QinetiQ-blogs.com.

For further information please contact:

John Haworth, Group Head of Investor Relations:

+44 (0) 7920 545841

Lorna Cobbett, Citigate Dewe Rogerson (Media enquiries):

+44 (0) 7771 344781

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBLGDSSXBDGDC
Date   Source Headline
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20249:32 amRNSHolding(s) in Company
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 202411:55 amRNSResult of Meeting
5th Feb 20243:48 pmRNSDirector/PDMR Shareholding
19th Jan 20249:31 amRNSDirector/PDMR Shareholding
16th Jan 20247:00 amRNSQ3 Trading Update and Share Buyback Programme
10th Jan 20245:00 pmRNSDirector/PDMR Shareholding
12th Dec 20232:38 pmRNSDirector/PDMR Shareholding
12th Dec 20232:32 pmRNSDirector Declaration
22nd Nov 20238:29 amRNSHolding(s) in Company
20th Nov 20237:00 amRNS$170m US new business contract win
16th Nov 20237:00 amRNSInterim Results
13th Nov 20239:58 amRNSDirector/PDMR Shareholding
25th Oct 20237:23 amRNSInvestor Seminar
17th Oct 20238:00 amRNSDirector Declaration
11th Oct 20237:00 amRNSSecond Quarter Trading Update
10th Oct 20233:56 pmRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNS$127m contract win in the US (formerly Avantus)
3rd Oct 20237:00 amRNS$84m contract win in the US
28th Sep 20233:24 pmRNSDirector/PDMR Shareholding
12th Sep 20235:54 pmRNSDirector/PDMR Shareholding
31st Aug 20235:03 pmRNS$224m contract win in the US (formerly Avantus)
25th Aug 20232:23 pmRNSDirector/PDMR Shareholding
10th Aug 20234:31 pmRNSDirector/PDMR Shareholding
27th Jul 20234:45 pmRNSDirector/PDMR Shareholding
20th Jul 20232:00 pmRNSResult of AGM
20th Jul 20237:00 amRNSFirst Quarter Trading Update
11th Jul 20235:30 pmRNSDirector/PDMR Shareholding
21st Jun 202312:15 pmRNSDirector/PDMR Shareholding
14th Jun 202310:00 amRNSHolding(s) in Company
12th Jun 20234:00 pmRNSDirector/PDMR Shareholding
12th Jun 20232:00 pmRNSAnnual Financial Report
25th May 20237:00 amRNSResults for the year ended 31 March 2023
10th May 20234:55 pmRNSDirector/PDMR Shareholding
17th Apr 20237:00 amRNSFourth Quarter Trading Update
12th Apr 202311:35 amRNSDirector/PDMR Shareholding
5th Apr 20237:00 amRNSQinetiQ announces £259 million renewal of MSCA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.